Table 5. Correlation between EHD2 expression and clinicopathologic parameters.
| Characteristic | EHD2 Immunostaining | p-value | |
|---|---|---|---|
| Low (n = 265) | High (n = 247) | ||
| Mean age (years) | 47.0 ± 13.6 | 47.0 ± 13.1 | 0.967 |
| Age | 0.446 | ||
| < 45 | 106 (49.8%) | 107 (50.2%) | |
| ≥ 45 | 159 (53.2%) | 140 (46.8%) | |
| Sex | 0.934 | ||
| Female | 210 (51.9%) | 195 (48.1%) | |
| Male | 55 (51.4%) | 52 (48.6%) | |
| Mean tumor size (cm) | 1.6 ± 0.8 | 1.6 ± 0.7 | 0.879 |
| Multifocality | 0.465 | ||
| Single | 146 (50.3%) | 144 (49.7%) | |
| Multiple | 119 (53.6%) | 103 (46.4%) | |
| Variants | 0.205 | ||
| Classic | 231 (51.2%) | 220 (48.8%) | |
| Follicular variant | 11 (68.8%) | 5 (31.2%) | |
| Tall cell variant | 8 (38.1%) | 13 (61.9%) | |
| Others | 15 (62.5%) | 9 (37.5%) | |
| Psammoma body | 0.001 | ||
| Negative | 211 (48.7%) | 222 (51.3%) | |
| Positive | 54 (68.4%) | 25 (31.6%) | |
| Dyscohesive cells | 0.010 | ||
| Absent | 98 (60.1%) | 65 (39.9%) | |
| Present | 167 (47.9%) | 182 (52.1%) | |
| pT stage | 0.776 | ||
| pT1-2 | 70 (50.7%) | 68 (49.3%) | |
| pT3-4 | 195 (52.1%) | 179 (47.9%) | |
| Extrathyroidal extension | 0.856 | ||
| Absent | 70 (51.1%) | 67 (48.9%) | |
| Present | 195 (52.0%) | 180 (48.0%) | |
| pN stage | 0.988 | ||
| pN0 | 82 (51.2%) | 78 (48.8%) | |
| pN1 | 168 (52.0%) | 155 (48.0%) | |
| PNx | 15 (51.7%) | 14 (48.3%) | |
| Lateral LN metastasis | 0.486 | ||
| Absent | 208 (51.0%) | 200 (49.0%) | |
| Present | 57 (54.8%) | 47 (45.2%) | |
| Distant metastasis | 0.774 | ||
| Absent | 261 (51.7%) | 244 (48.3%) | |
| Present | 4 (57.1%) | 3 (42.9%) | |
| AJCC stage | 0.624 | ||
| I | 121 (48.8%) | 127 (51.2%) | |
| II | 50 (53.8%) | 43 (46.2%) | |
| III | 67 (55.4%) | 54 (44.6%) | |
| IV | 27 (54.0%) | 23 (46.0%) | |
| BRAF V600E mutation | < 0.001 | ||
| Absent | 54 (72.0%) | 21 (28.0%) | |
| Present | 169 (47.9%) | 184 (52.1%) | |
| Persistent/Recurrent disease | 0.636 | ||
| Absent | 245 (51.5%) | 231 (48.5%) | |
| Present | 20 (55.6%) | 16 (44.4%) | |
PTC, papillary thyroid carcinoma; LN, lymph node.